AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 12 - (NewsRx.com & NewsRx.net) -- Digene Corporation (DIGE) announced that the U.S. Patent and Trademark Office granted the company a patent pertaining to the use of gene expression levels to assess the progression of HPV infection from benign to malignant growth.
The new patent, U.S. Patent No. 6,355,424 B1 entitled "Assessment of Human Papillomavirus-Related Disease," provides for assessing the stage of HPV-induced disease in the form of an assay that can be combined with other assays to improve the accuracy and reliability of prognostic and diagnostic assessments of HPV-based cervical disease.
A Notice of Acceptance from the Australian Patent Office has also been received. In the future, cervical cancer screening programs may utilize this tool as a method for identifying patients who are currently infected with HPV and at risk for having or developing disease from those infected but not at risk for progression to disease.
Attila Lorincz, ...
Source: HighBeam Research, New patent granted related to methods for assessment of HPV-induced...